Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Taxes (2016 - 2018)

Enanta Pharmaceuticals filings provide 5 years of Current Taxes readings, the most recent being $5.9 million for Q4 2018.

  • On a quarterly basis, Current Taxes fell 42.89% to $5.9 million in Q4 2018 year-over-year; TTM through Dec 2018 was $5.9 million, a 42.89% decrease, with the full-year FY2018 number at $1.4 million, down 85.07% from a year prior.
  • Current Taxes hit $5.9 million in Q4 2018 for Enanta Pharmaceuticals, up from $1.4 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $16.9 million in Q4 2014 to a low of $1.2 million in Q3 2015.
  • Median Current Taxes over the past 5 years was $5.6 million (2018), compared with a mean of $6.8 million.
  • Biggest five-year swings in Current Taxes: surged 31.99% in 2016 and later tumbled 85.07% in 2018.
  • Enanta Pharmaceuticals' Current Taxes stood at $16.9 million in 2014, then tumbled by 70.76% to $4.9 million in 2015, then plummeted by 40.45% to $2.9 million in 2016, then surged by 248.64% to $10.3 million in 2017, then plummeted by 42.89% to $5.9 million in 2018.
  • The last three reported values for Current Taxes were $5.9 million (Q4 2018), $1.4 million (Q3 2018), and $5.4 million (Q1 2018) per Business Quant data.